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658Objectives: Analyses of mechanical circulatory support (MCS) in pediatric heart surgery have primarily
focused on single-center outcomes or narrow applications. We describe the patterns of use, patient characteris-
tics, and MCS-associated outcomes across a large multicenter cohort.
Methods: Patients (aged<18 years) in the Society of Thoracic Surgeons (STS) Congenital Heart Surgery Data-
base (2000-2010) were included. The characteristics and outcomes of those receiving postoperative MCS were
described, and bayesian hierarchical models were used to examine variations in the adjusted MCS rates across
institutions.
Results:Of 96,596 operations (80 centers), MCS was used in 2.4%. The MCS patients were younger (13 vs 195
days, P<.0001) and more often had STS-defined preoperative risk factors (57.2% vs 32.7%, P<.0001). The
operations with the greatest MCS rates included the Norwood procedure (17%) and complex biventricular re-
pairs (arterial switch, ventricular septal defect, and arch repair [14%]). More than one half of the MCS patients
did not survive to hospital discharge (53.2% vs 2.9% of non-MCS patients; P<.0001). MCS-associated mor-
tality was greatest for truncus arteriosus and Ross-Konno operations (both 71%). The hospital-level MCS rates
adjusted for patient characteristics and case mix varied by 15-fold across institutions, with both high- and low-
volume hospitals having substantial variation in MCS rates.
Conclusions: Perioperative MCS use varied widely across centers. The MCS rates were greatest overall for the
Norwood procedure and complex biventricular repairs. Although MCS can be a life-saving therapy, more than
one half of MCS patients will not survive to hospital discharge, with mortality>70% for some operations.
Future studies aimed at better understanding the appropriate indications, optimal timing, and management of
MCS could help to reduce the variation in MCS use across hospitals and improve outcomes. (J Thorac Cardi-
ovasc Surg 2014;147:658-65)Mechanical circulatory support (MCS) has been used peri-
operatively in the care of critically ill children with congen-
ital heart disease and is often life-saving. Although several
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the most common form of pediatric MCS has been extracor-
poreal membrane oxygenation (ECMO). ECMO can be
rapidly and simply initiated. It was first used in a pediatric
patient in 1974 at Orange County Medical Center (Los
Angeles, Calif), and Robert Bartlett, MD, first successfully
supported a neonate with ECMO (to treat meconium aspira-
tion).1 Since then, the application of ECMO has expanded
to include cardiopulmonary support of patients with
congenital heart disease. As the surgical repair of congenital
heart disease has become increasingly complex, ECMO use
has become more common. Reports of its use in this popu-
lation have included bridging to heart transplantation,
rescue cardiopulmonary resuscitation, and failure to wean
from cardiopulmonary bypass.2-4 However, these reports
have primarily included small cohorts, were most often
from single institutions, and tended to be narrowly
focused on a specific patient population. Currently,
understanding is limited regarding the use and outcomes
associated with ECMO after congenital heart surgery
across institutions.ery c February 2014
Abbreviations and Acronyms
ECMO ¼ extracorporeal membrane oxygenation
ELSO ¼ Extracorporeal Life Support Organization
MCS ¼ mechanical circulatory support
STS ¼ Society of Thoracic Surgeons
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DThe Society of Thoracic Surgeons (STS) Congenital
Heart Surgery Database collects perioperative information
on all patients at participating institutions undergoing pedi-
atric and congenital heart surgery, including information
regarding the use of perioperative MCS. Approximately
85% of all US pediatric heart surgery centers participate
in this database, and, therefore, it is a valuable repository
of information regarding the use of MCS in congenital heart
surgery patients.5 The primary objective of the present
study was to use the STS Congenital Heart Surgery Data-
base to describe the patterns of use, patient characteristics,
and outcomes associated with MCS across a large multi-
center cohort.METHODS
Data Source
The STS Congenital Heart Surgery Database contains operative, periop-
erative, and outcomes data on >250,000 patients who have undergone
congenital heart surgery since 1998 and currently includes information
from 105 participating hospitals. Data from all patients undergoing pediatric
and congenital heart surgery at participating centers are entered into the data-
base. Data quality and reliability are ensured through intrinsic verification of
data and a formal process of site visits and data audits.6 The Duke Clinical
Research Institute serves as the data warehouse and analytic center for all
STS national databases. The Duke University institutional review board
and STS Access and Publications Committee approved the present analysis.
Patient Population
For the present study, 1,32,854 cardiac operations (with or without car-
diopulmonary bypass) performed on patients aged<18 years from 2000 to
2010 at 96 hospitals participating in the STS Congenital Heart Surgery
Database were eligible for inclusion. A total of 16 centers with>15%
missing data on study variables were excluded. Although the STS DATA-
BASE contains nearly complete data for the standard data fields required to
calculate operative mortality, not all centers submit complete data for all
variables, such as patient preoperative characteristics or postoperative
complications. Therefore, it has been standard practice to exclude centers
with data missing for key study variables to maximize data integrity and
minimize missing data.7 From the remaining 80 centers, the patients
with data missing for the study variables were also excluded, leaving a final
study population of 96,596 patients.
Data Collection
The data collected from the STS Congenital Heart Surgery Database
included demographic information, cardiac diagnoses, presence of a
noncardiac/genetic abnormality, and the presence of any STS-defined pre-
operative risk factors.8 The operative data included information regarding
the primary procedure of the index (first) cardiovascular operation of the
admission, which was analyzed individually and also categorized using
the STS-European Association for Cardiothoracic Surgery risk stratifica-
tion system (category 1, lowest mortality risk; category 5, greatestThe Journal of Thoracic and Camortality risk).9 This system was recently developed using empiric data
from nearly 80,000 patients and includes a greater number of operations
than other risk stratification systems.9 The number of previous cardiotho-
racic operations and cardiopulmonary bypass times were also collected.
The use of both pre- and postoperative MCS (of any type) was collected.
In the earlier years of data collection, detailed information regarding the
specific type of MCS was not collected in the database; therefore, the pre-
sent study analyzed MCS use in aggregate. In addition, detailed informa-
tion regarding the timing of the initiation and duration of MCS is not
currently collected in the database. The outcomes data included in-
hospital mortality and postoperative length of stay.
Statistical Analysis
The preoperative, operative, and outcomes data were described for the
overall cohort and for the subgroups of patients undergoing the most com-
mon operations using standard summary statistics. The data were compared
between those who received MCS and those who did not using the chi-
square test or Wilcoxon rank sum test. Most of the analysis focused on post-
operative MCS use, given the relative rarity of preoperative MCS use.
To examine the variation in postoperative MCS rates across hospitals,
bayesian hierarchical models were used to calculate the adjusted postoper-
ative MCS rates for each hospital. The models were adjusted for patient
characteristics and case mix to account for any differences across hospitals,
including patient age, gender, weight at surgery, the presence of any STS-
defined preoperative risk factors or noncardiac/genetic abnormality, previ-
ous cardiothoracic surgery, the use of preoperative MCS, STS-European
Association for Cardiothoracic Surgery category, and date of surgery.
This method also accounted for the increased variability in outcomes
from centers with a smaller sample size and shrinks the estimates form
smaller centers toward the population average to provide more stable esti-
mates.10 The distribution of adjusted MCS rates across hospitals was
described and plotted against the hospital-average annual overall cardiac
surgical volume. Finally, to further investigate the relationship between
center volume and MSC rates, we also calculated the adjusted MCS rates
across center volume categories (<150, 150-249, 250-349, and 350 total
cardiac cases annually) as follows: adjusted rate¼ observed rate/predicted
rate3 sample average rate, where the predicted rates were from a marginal
logistic model, including the aforementioned patient and operative factors.
All analyses were performed using Statistical Analysis Systems, version
9.3 (SAS Institute, Inc, Cary, NC), and WinBUGS, version 1.4.3 (the
Bayesian inference Using Gibbs Sampling project, Cambridge, UK).
P<.05 was considered statistically significant.RESULTS
A total of 96,596 congenital cardiac operations from 80
hospitals were included. The included hospitals were diverse
geographically (44% South, 24%Midwest, 21%West, and
11% Northeast). The overall MCS rate was 2.8%
(n ¼ 2750), including preoperatively (0.5%; n¼ 463), post-
operatively (2.2%; n ¼ 2136), or both (0.1%; n ¼ 151).
Additional analysis focused on the group receiving any post-
operativeMCS (n¼ 2287, 2.4%). ECMO support accounted
for>95% of the instances of postoperative MCS.Study Population Characteristics
The characteristics of the study cohort overall and those
who received postoperative MCS and those who did not are
listed in Table 1. The patients receiving postoperative MCS
were younger, weighed less, and more often had an STS-
defined preoperative risk factor than did the patients withoutrdiovascular Surgery c Volume 147, Number 2 659
TABLE 1. Patient characteristics, operative characteristics, and outcomes of study population
Characteristic Overall (n ¼ 96,596)
Postoperative MCS use
P valueYes (n ¼ 2287) No (n ¼ 94,309)
Patient
Age (d) 189 (28-1227) 13 (5-124) 195 (31-1259) <.0001
Weight (kg) 6.3 (3.5-14.2) 3.4 (2.9-5.1) 6.4 (3.6-14.4) <.0001
White race 47,605 (49.3) 1094 (47.8) 46,511 (49.3) <.0001
Male gender 52,670 (54.5) 1262 (55.2) 51,408 (54.5) .004
Noncardiac abnormality 29,464 (30.5) 677 (29.6) 228,787 (30.5) .3
STS preoperative risk factors
Any 32,115 (33.3) 1310 (57.3) 30,805 (32.7) <.0001
Mechanical ventilation 15,303 (15.8) 837 (36.6) 14,466 (15.3) <.0001
Arrhythmia 2206 (2.6) 90 (4.6) 2116 (2.6) <.0001
Shock 1727 (1.8) 170 (7.4) 1047 (1.7) <.0001
Operative
Previous CT operation 26,939 (27.9) 458 (20.0) 26,481 (28.1) <.0001
STAT category
Low (1-3) 69,447 (71.9) 581 (25.4) 68,866 (73.0) <.0001
High (4-5) 23,756 (24.6) 1653 (72.3) 22,103 (23.4) <.0001
CPB time (min) 95 (64-140) 175 (121-252) 94 (63-137) <.0001
Outcomes
In-hospital mortality 3940 (4.1) 1217 (53.2) 2723 (2.9) <.0001
Length of stay (d) 6 (4-14) 28 (12-56) 6 (4-13) <.0001
Data presented as n (%) or median (interquartile range) for continuous variables. MCS, Mechanical circulatory support; STS, Society of Thoracic Surgeons; STAT, Society of
Thoracic Surgeons–European Association for Cardiothoracic Surgery; CT, cardiothoracic; CPB, cardiopulmonary bypass.
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DMCS. The patients receiving MCS were more likely to have
received a preoperative shock (7.4% vs 1.7%), to have pre-
operative arrhythmia (4.6% vs 2.6%), and to have been
mechanically ventilated (36.6% vs 15.3%). No clinically
meaningful differences were found in race/ethnicity,
gender, or the proportion with a noncardiac/genetic abnor-
mality in the MCS and non-MCS groups. The operative
characteristics are also listed in Table 1. The MCS cohort
was more likely to have undergone higher complexity oper-
ations involving longer cardiopulmonary bypass times.Overall Outcomes
More than one half of those who received postoperative
MCS did not survive to hospital discharge (Table 1). TheTABLE 2. Operations with highest postoperative MCS rates and associate
Operation
Total
cases (n)
MCS
rate (%)
Mortal
MCS
Norwood procedure 3272 17 5
ASO þ VSD þ aortic arch repair 139 14 4
Damus-Kaye-Stansel 430 13 4
Truncus arteriosus repair 689 9.4 7
Ross-Konno operation 225 9.3 7
Unifocalization MAPCA 466 8.4 4
TAPVC repair 1850 8.2 5
ASO þ VSD 855 7.5 5
ALCAPA repair 397 7.3 1
MCS, Mechanical circulatory support; ASO, arterial switch operation; VSD, ventricular sep
pulmonary venous connection; ALCAPA, anomalous origin of coronary artery from pulmo
660 The Journal of Thoracic and Cardiovascular Surgin-hospital mortality was 53.2% compared with 2.9% for
those who did not receive MCS (P<.0001). As expected,
the length of stay was prolonged for those who received
MCS (median 28 vs 6 days; P<.0001; Table 1).PostoperativeMCSRates and Outcomes for theMost
Common Operations
Operations with>100 patients in the overall cohort were
evaluated further. Those with the greatest postoperative
MCS rates are listed in Table 2. The greatest rates of
MCS were observed for the Norwood procedure (17.0%)
and for complex biventricular repairs including the arterial
switch plus ventricular septal defect plus aortic arch repair
operation (14.0%), truncus arteriosus repair (9.4%), andd outcomes
ity with
(%)
Mortality without
MCS (%)
Unadjusted OR
(MCS vs no MCS) P value
7 13 8.7 <.0001
0 3 19.2 <.0001
0 10 6.0 <.0001
1 5.5 42.0 <.0001
1 3.4 70.4 <.0001
1 8 8.0 <.0001
9 7.4 18.1 <.0001
3 3.2 34.7 <.0001
4 1 19.5 <.0001
tal defect;MAPCA, major aortopulmonary collateral artery; TAPVC, total anomalous
nary artery.
ery c February 2014
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Dthe Ross-Konno procedure (9.3%). Of all of the operations
examined, postoperativeMCSwas associated with a greater
risk of in-hospital mortality. This risk was greatest for the
Ross-Konno procedure (mortality with MCS, 71%; vs
without MCS, 3.4%; unadjusted odds ratio, 70.4;
P< .0001) and truncus arteriosus repair (mortality with
MCS, 71%; vs without MCS, 5.5%; unadjusted odds ratio,
42.0; P<.0001).
The STS-defined ‘‘benchmark’’ operations of varying
levels of complexity were also evaluated (Norwood proce-
dure, truncus arteriosus repair, Fontan operation, arterial
switch operation with or without ventricular septal defect
repair, tetralogy of Fallot repair, complete atrioventricular
canal repair, and ventricular septal defect repair), in addi-
tion to bidirectional Glenn/hemi-Fontan and atrial septal
defect repair. The MCS rates and associated outcomes for
these operations are displayed in Figure 1. As expected,
the MCS rates increased with operation complexity. The
MCS rate was>5% for 3 of these 10 common operations.
Postoperative MCS use was associated with greater in-
hospital mortality for all the benchmark operations.Variation in Postoperative MCS Rates Across
Hospitals
The variation in postoperative MCS rates across hospi-
tals, adjusted for any differences in patient characteristics
and case mix, was evaluated. As displayed in Figure 2,
the median hospital level–adjusted MCS rate was 2.5%
and varied from 0.6% to 9.3% across the 80 hospitals
included in the present study (15-fold variation). We also
examined the relationship of the overall cardiac surgical
volume with the adjusted MCS rate. Although lower vol-
ume hospitals as a group had slightly greater MCS rates
(Figure 3), the magnitude of this difference was relativelyFIGURE 1. Postoperative mechanical circulatory support (MCS) rates for benc
ventricular septal defect; BDG/HF, bidirectional Glenn/hemi-Fontan; TOF, tetra
operation; ASO/VSD, arterial switch operation/ventricular septal defect; TA, tru
The Journal of Thoracic and Casmall, and a plot of each hospital’s MCS rate versus total
surgical volume did not demonstrate a clear overall rela-
tionship. Both high- and low-volume hospitals appeared
to have substantial variation in MCS rates.DISCUSSION
The present report, which used data from the STS
Congenital Heart Surgery Database, focused on the patterns
of use and outcomes associated with postoperative MCS.
We found that the MCS rates were>5% in nearly one third
of the most common congenital cardiac operations per-
formed and were greatest for neonates undergoing single
ventricle palliative procedures and complex biventricular
repairs. Despite being a potentially lifesaving therapy,
more than one half of patients receiving MCS will not sur-
vive to hospital discharge, and the MCS-associated in-
hospital mortality for some operations has been>70%.
The variation in MCS rates across hospitals was substantial,
including both high- and low-volume centers.
MCS remains an emerging technology. Devices such as
the intra-aortic balloon pump and ventricular assist pumps
were initially developed primarily to meet the needs of adult
patients, and the occasional application in the pediatric pop-
ulation was limited to relatively large patients. The emer-
gence and refinement of ECMO support for respiratory
failure in neonates and infants have led logically to the
application of similar technology for cardiopulmonary sup-
port and to increasingly frequent use in patients with
congenital heart disease. Although ECMO is still by far
the most widely used form of MCS in pediatric cardiac sur-
gery, it has recently been joined by alternative devices for
univentricular or biventricular support.
The relatively young median age and lower weight for
those receiving postoperative MCS was not surprising.hmark procedures and associated mortality. ASD, Atrial septal defect; VSD,
logy of Fallot; CAVC, complete atrioventricular canal; ASO, arterial switch
ncus arteriosus; Nwood, Norwood.
rdiovascular Surgery c Volume 147, Number 2 661
FIGURE 2. Variation in adjusted mechanical circulatory support (MCS)
rates across hospitals. Adjusted postoperative MCS rates are listed for
each hospital (black box represents adjusted estimate; lines, 95% confi-
dence intervals). The horizontal dotted line indicates the postoperative
MCS rate in the overall cohort.
FIGURE 3. Relationship of adjusted mechanical circulatory support
(MSC) rates with total surgical volume across hospitals. Adjusted postop-
erative MCS rates are listed for each hospital in order of increasing average
annual total cardiac surgical volume (black box represents adjusted esti-
mate; lines, 95% confidence intervals). The horizontal dotted line indicates
the postoperativeMCS rate in the overall cohort. The adjustedMCS rates in
volume groups are also listed at the bottom of the plot.
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DImprovements in perioperative care of the neonate with
congenital heart disease has led to increased interest in early
operative intervention in this population.11 Even in the
setting of acceptable anatomic reconstruction, animal
studies and clinical observation have suggested that the
neonatal myocardium is uniquely susceptible to ischemia–
reperfusion injury.12,13 Published reports have also
demonstrated that the presence of various preoperative
risk factors increase the morbidity and mortality after
complex neonatal repairs.14 Although survival has
improved significantly in complex operations during the
past 2 decades, these operations (including the Norwood
procedure, arterial switch/aortic arch repair, and truncus/in-
terrupted aortic arch repair) have been shown to have the
greatest mortality risk of all congenital heart surgery
operations.15
The in-hospital mortality and length of stay we have
reported were comparable and perhaps slightly lower than
previously published data, including data from reports
from the Extracorporeal Life Support Organization
(ELSO) database.16,17 An ELSO study from 1989 to 2004
that included 5151 neonatal and pediatric cardiac cases
reported that the in-hospital mortality for the neonatal and
pediatric cardiac cohorts was 62% and 57%, respectively.
The subgroups examined included congenital defect,
cardiac arrest, cardiogenic shock, cardiomyopathy, and
myocarditis. The investigators also reported the incidence
of mechanical and patient-related complications of662 The Journal of Thoracic and Cardiovascular SurgECMO in the cardiac population. The most common
complication in each group was oxygenator failure
(7.2%) and surgical site bleeding (31.0%). Unlike the pre-
sent study, the ELSO study did not report on specific patient
characteristics, preoperative risk factors, operative charac-
teristics, individual congenital heart lesions, or interhospital
variation.
The Norwood procedure had the greatest postoperative
MCS rate in the present study. This operation can be 1 of
the most challenging operations in congenital heart surgery,
and it can be difficult to reliably reproduce technically per-
fect results.18 In addition, the resulting physiology is precar-
ious and sensitive to minor changes in preload, afterload,
and contractility. This has been highlighted by the 13%
mortality in the present study in those Norwood patients
who did not receive MCS. However, it is also important
to note that the subgroup with the greatest mortality associ-
ated with MCS in the present study was not the single
ventricle patients, but those patients undergoing biventricu-
lar repairs, including truncus arteriosus and Ross-Konno
operations. Because no risk models have been established
and validated for these relatively uncommon operations,
which are sometimes performed on infants with severe
physiologic embarrassment, we can only speculateery c February 2014
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Dregarding the specific reasons for the increased risk of mor-
tality in patients receiving MCS after these procedures.
Some common features include right ventriculotomy, the
presence of many aortic suture lines that could exacerbate
bleeding during MCS use, and the potential for coronary
insufficiency with both repairs (coronary buttons and reim-
plantation usually for the Ross-Konno; abnormal coronary
orifice locations possible in truncus arteriosus). What
remains unclear is the relative contribution of patient fac-
tors and procedural factors to the need for, and ultimate
salvage rate associated with, postoperative MCS. The bal-
ance of preoperative physiologic compromise, intraopera-
tive myocardial ischemia and reperfusion, and the
technical complexity of the operations (in particular, with
respect to the restoration of adequate coronary artery anat-
omy and perfusion and the potential for residual defects and
hemodynamic burdens) constitute a complex field of vari-
ables that might influence the need for MCS at separation
from cardiopulmonary bypass or the likelihood of postoper-
ative deterioration requiring resuscitation. It was not at all
surprising, then, that operations such as the palliative Nor-
wood procedure, repair of transposition with ventricular
septal defect and arch obstruction, and the neonatal Ross-
Konno procedure have been associated with the greatest
rates of MCS. What remains to be determined is how best
to take advantage of the available technology to maximize
salvage of these patients.19,20
Although the mortality associated with MCS was high at
53%, it is important to recognize that likely few to none of
these patients would have been discharged alive without the
use of MCS. Nonetheless, the wide variability in MCS rates
we observed across centers, even after accounting for poten-
tial differences in case mix and patient characteristics, sug-
gests ample room exists for improvement. Additional study
is necessary to better understand the reasons underlying this
variation, and whether the variation in MCS rates is associ-
ated with the known variation in mortality rates across hos-
pitals.21,22 Although the reasons for the wide variability in
MCS rates across centers are not obvious, there are
several potential explanations. The interval from the
inception and rate of maturation of individual institutional
ECMO (and other MCS) programs varied from center to
center. Likewise, the threshold for instituting mechanical
support reflects the judgment and experience of the
individual surgeons and multidisciplinary critical care
teams. In some centers, postoperative MCS might be
limited to patients who cannot be weaned from
cardiopulmonary bypass or who experience cardiac arrest
in the intensive care unit. In others, mechanical support
might be considered earlier and more frequently as a
desirable alternative to escalating pharmacologic support.
What is apparent is that MCS for postoperative support is
used in the vast majority of centers, consistent with the
Quality Measures for Congenital and Pediatric CardiacThe Journal of Thoracic and CaSurgery proposed by the STS, which include the
availability of an institutional pediatric extracorporeal life
support program.23
Study Limitations
The primary limitations of the present study were related
to the nature of the STS database. Not all US centers partic-
ipate in the STS database or submit complete data. None-
theless, the present report represents the most broad
evaluation of MCS use to date, including 80 US pediatric
heart centers. In addition, in the earlier years of data collec-
tion, detailed information regarding the specific type of
MCS was not collected in the database; therefore, we
were limited to analyzing postoperative MCS use in aggre-
gate. The addition of specific fields related to the use of ven-
tricular assist devices in more recent versions of the data
collection form will allow more detailed analyses of spe-
cific types of perioperative MCS in the future. The database
also currently does not collect details regarding the indica-
tion forMCS support or other details related toMCS such as
flow rates, specific duration of therapy, and MCS-related
complications. Significant interhospital variation likely
exists in many aspects of clinical care, including, but not
limited to, anticoagulation, pump flow, vasoactive medica-
tion management, and weaning protocols. Future linkage of
the STS Congenital Heart Surgery Database with the ELSO
database could potentially address some of these limitations
and allow analyses currently not possible using either data
set alone. Finally, the database currently does not collect
longer term follow-up data to evaluate the functional capac-
ity and long-term survival of those patients receiving MCS.
CONCLUSIONS
Although MCS can be a life-saving therapy for children
undergoing heart surgery, more than one half of children
who receive MCS will not survive to hospital discharge,
with MCS-associated mortality>70% for certain opera-
tions. AlthoughMCSwas used most commonly in those un-
dergoing single ventricle palliative procedures, MCS was
also common for patients undergoing complex biventricular
repairs, and the greatest mortality risk was associated with
MCS in this latter group. MCS use varied widely across hos-
pitals (15-fold), even after accounting for any differences
in case mix or patient characteristics, suggesting ample
room for improvement. Future studies aimed at better
understanding and standardizing indications for MCS,
optimal timing, andMCSmanagement might help to reduce
the variation across hospitals and improve outcomes.
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Dr James Tweddell (Milwaukee, Wis). I would like to thank
The American Association for Thoracic Surgery (AATS) for
asking me to discuss this report. Chris, that was really a terrific pre-
sentation. You and your colleagues have explored the STS
Congenital Heart Surgery Database for information on mechanical
support among patients undergoing congenital heart surgery.
Among almost 97,000 operations, the rate of MCS was 2.8%, or
2750 cases. Of these 2750 patients, 17% received support preoper-
atively, 78% postoperatively, and 5% were fortunate enough to
receive both preoperative and postoperative circulatory support.
More than 95% of the patients were supported using ECMO;
thus, we can really consider this a study of perioperative ECMO
support.
Not surprisingly, the patients receiving MCS were younger,
smaller, and more likely to have the preoperative risk factors of
shock, in particular, mechanical ventilation and arrhythmias, and
were more likely to require more complex procedures.
Just to be clear, to be included in the present study, there must
have been an operation for congenital heart disease. Thus, patients
admitted with acute myocarditis or dilated cardiomyopathy or
receiving mechanical support as a bridge to recovery or transplan-
tation would not have been included, is that correct?
Dr Mascio. That is correct.
Dr Tweddell. In addition, as you said, we do not have data on
the indications for mechanical support such as inotrope score or
any surrogates or measures of cardiac output or the use of cardio-
pulmonary resuscitation (CPR) at the timemechanical support was
initiated.
Dr Mascio. Correct. The database did not track the inotrope
score, measures of cardiac output, or the use of CPR during the
study period (2000-2010).
Dr Tweddell. What was most dramatic to me was the plot of
MCS use versus center volume. Naively, perhaps, I would have
anticipated that larger volume centers would have used MCS
less than would lower volume centers. The center variation was
tremendous. This really illuminates the dramatic differences in
practice patterns among centers. If you have seen 1 congenital
heart surgery program, you have seen 1 congenital heart surgery
program.
Did you explore any of the variations in practice patterns?
Could you tell us whether a difference existed in the
complexity–adjusted survival rates of MCS between those pro-
grams using MCS frequently and those using it very little?
DrMascio.We compared theMCS rate with the volume but did
not examine survival at high versus low use centers.
Dr Tweddell. Was there a difference in survival between the
high- and low-volume centers with MCS?
Dr Mascio. We do not know from the present study. A slight
difference was present in the rate of mechanical support, but it
was likely not clinically significant.
Dr Tweddell. You stated in your report, which was very well-
written, that you studied the regional differences in the United
States—northeast, south, west, et cetera. Did you see any differ-
ences or any consistency in the MCS used in the different regions?
DrMascio.We examined the location, but not the regional rate
of use of MCS, of the 80 included centers.ery c February 2014
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DDr Tweddell. Well, overall, the mortality was >50% and
certainly MCS in the perioperative setting is expensive and highly
morbid. Clearly, we need some additional information on the indi-
cations for MCS. The next few questions really concern how we
should proceed next.
Would you recommend that we add some data fields to the STS
database in the future? Keeping in mind the substantial burden of
the number of fields we already have.
Dr Mascio. Yes, I would. In fact, in the newest STS database
form they have already added fields, including the type of assist de-
vice, the indication for initiation, and the reason for termination of
support. Starting this summer, that form will be used and that
information will be tracked.
Dr Tweddell. You also mentioned the ELSO database. Do you
think there is an opportunity to go back with these data and the
ELSO registry, such as Sara Pasquali has done for antifibrinolytics,
to determine whether we can at least tease out who was receiving
CPR at ECMO initiation?
Dr Mascio. I think so, because those 2 databases follow
different data points. The ELSO database definitely has an extra-
corporeal CPR group that they follow and they also follow postop-
erative complications after ECMO. So I think using both databases
can certainly provide us with some data that each one individually
could not.
Dr Tweddell.Do you think it would beworthwhile trying to put
together some sort of survey of North American centers to identify
the indications forMCS?We could thenmatch the indications with
outcomes and potentially identify the best practices?
Dr Mascio. Yes, absolutely—and not just for indications, but
for management also. For example, for anticoagulation manage-
ment, some centers use anti-Xa levels, some centers use the acti-
vated clotting time, some centers use the partial thromboplastin
time, and some use a combination of all of those.
Dr Tweddell. That was an excellent presentation. Just as with
all very good reports, you have identified more questions for us
to answer in the future. Thank you.
Dr Mascio. Thank you very much.
Dr V. Mohan Reddy (Stanford, Calif). Chris, I have 1 question
for you. In your analysis, considering ECMO and the length of
ECMO, was there any duration of ECMO beyond which it was
futile and was discontinued?
DrMascio.The STS database during the 2000 to 2010 period did
not follow that; thus,wedo not know the reason for the initiation and/
or termination or the duration of support. We just know the patients
had undergone an index operation that was followed by MCS.
DrReddy. Thus, obviously, if it was just a pure myocardial fail-
ure and the patient is receiving ECMO for that, I would suspect
that beyond a certain period the myocardium is unlikely to recover.
DrMascio. From our findings, we could not really state that af-
ter 48 or 72 hours, or any duration for that matter, that ECMO
should be discontinued. The end point we considered was in-hos-
pital mortality.
Dr Reddy. I think it would be worthwhile data to gather from
any database, because it would be important to know that beyond
a certain period it is not worth continuing it.The Journal of Thoracic and CaDr Mascio. I agree.
Dr Christian Pizarro (Wilmington, Del). Very nice presenta-
tion. Do you have any data that can help us understand why was
it that although the Norwood patients tended to be supported
more often, some of those complex ventricular repairs had the
highest mortality? Also, if not, could you elaborate from what
you know how that could be explained?
Dr Mascio. From the present study, no. Others have reported
truncus arteriosus repair and Ross-Konno operation as very
high-risk operations. In the present study, Norwood mortality,
even without mechanical support, was 13%. The present study
cannot explain why mechanical support for some biventricular re-
pairs was associated with very high mortality.
Dr Carl L. Backer (Chicago, Ill). Chris, congratulations on a
terrific study. As Dr Tweddell said, this review might have opened
up more questions than answers. However, it is important and eye-
opening to realize that there is a 57% mortality rate for putting a
patient on ECMO after a Norwood procedure. Many centers now
experience external pressures on cost containment and I believe
that at some point, we might not be able to afford this therapy. It
will be up to us to decide who is going to receive ECMO and
who is not, from both a quality of life standpoint and a careful
use of resources standpoint. We are going to have to somehow
figure this out.
I agree that the idea of a survey proposed by Dr Tweddell is a
very good one. Perhaps we could then develop consensus-based
guidelines for using ECMO in the postoperative period. At some
centers, no patient dies without first receiving ECMO. We need
to decide whether this is in the best interest of the patient and
the family. Consider a neonate with heterotaxy, total veins, pulmo-
nary atresia, an unbalanced atrioventricular septal defect, and
severe postoperative atrioventricular valve insufficiency. Perhaps
that patient should not be receiving ECMO automatically for
severe ventricular dysfunction after the operation. It will be incum-
bent on us as a group to determine this before external forces tell us
when we can and cannot use ECMO. Do you have any thoughts on
this socioeconomic issue?
Dr Mascio. I think that doing a survey is a very good idea.
When we were writing our report, we were careful to use the
phrase ‘‘receiving mechanical support’’ and not ‘‘requiring me-
chanical support.’’ Because, as you said, it is different for every
institution. Some institutions use ECMO for all patients, and
some would take a patient such as you just described and not offer
MCS.
Dr V.Mohan Reddy (Stanford, Calif). I think it might probably
be worthwhile to have a task force similar to the American Heart
Association task force that can develop guidelines for ECMO,
when to start and whom to start and when to discontinue. It might
be something the Association might consider.
Further Discussion by James Tweddell, MD
Dr Tweddell (Milwaukee, Wis). The last comment, the rate of
ECMO support for the Norwood procedure was 17% in the present
study, which goes back many years; 15% in the Single Ventricle
Reconstruction trial. Thus, I think it is pretty much within the
range of what many institutions experience.rdiovascular Surgery c Volume 147, Number 2 665
